DDInter853 DDInter1676
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Haloperidol {u} (Compound) resembles {v} (Compound) Bepotastine
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Haloperidol {u} (Compound) resembles {v} (Compound) Sertindole
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Haloperidol {u} (Compound) binds {v} (Gene) CYP2C9
Haloperidol {u} (Compound) palliates {v} (Disease) schizophrenia
Haloperidol {u} (Compound) downregulates {v} (Gene) CDC20
Haloperidol {u} (Compound) causes {v} (Side Effect) Extrapyramidal disorder
Haloperidol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Haloperidol {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Haloperidol (Compound) resembles Bepotastine (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Haloperidol (Compound) resembles Sertindole (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Haloperidol (Compound) binds CYP2C9 (Gene)
Haloperidol (Compound) palliates schizophrenia (Disease)
Haloperidol (Compound) downregulates CDC20 (Gene)
Haloperidol (Compound) causes Extrapyramidal disorder (Side Effect)
Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Haloperidol may lead to a major life threatening interaction when taken with Anagrelide